Literature DB >> 33214225

Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases.

Catherine A Hurd1, Paul Brear1, Jefferson Revell2, Sarah Ross3, Helen R Mott4, Darerca Owen5.   

Abstract

Ral GTPases have been implicated as critical drivers of cell growth and metastasis in numerous Ras-driven cancers. We have previously reported stapled peptides, based on the Ral effector RLIP76, that can disrupt Ral signaling. Stapled peptides are short peptides that are locked into their bioactive form using a synthetic brace. Here, using an affinity maturation of the RLIP76 Ral-binding domain, we identified several sequence substitutions that together improve binding to Ral proteins by more than 20-fold. Hits from the selection were rigorously analyzed to determine the contributions of individual residues and two 1.5 Å cocrystal structures of the tightest-binding mutants in complex with RalB revealed key interactions. Insights gained from this maturation were used to design second-generation stapled peptides based on RLIP76 that exhibited vastly improved selectivity for Ral GTPases when compared with the first-generation lead peptide. The binding of second-generation peptides to Ral proteins was quantified and the binding site of the lead peptide on RalB was determined by NMR. Stapled peptides successfully competed with multiple Ral-effector interactions in cellular lysates. Our findings demonstrate how manipulation of a native binding partner can assist in the rational design of stapled peptide inhibitors targeting a protein-protein interaction.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GTPase; K-Ras; RLIP76; Ral; cancer; cell signaling; chemical biology; drug discovery; protein-protein interaction; stapled peptides

Year:  2020        PMID: 33214225      PMCID: PMC7949049          DOI: 10.1074/jbc.RA120.015735

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

Review 2.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

3.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors:  Federico Bernal; Andrew F Tyler; Stanley J Korsmeyer; Loren D Walensky; Gregory L Verdine
Journal:  J Am Chem Soc       Date:  2007-02-07       Impact factor: 15.419

4.  Mutational analysis reveals a single binding interface between RhoA and its effector, PRK1.

Authors:  Catherine L Hutchinson; Peter N Lowe; Stephen H McLaughlin; Helen R Mott; Darerca Owen
Journal:  Biochemistry       Date:  2011-03-16       Impact factor: 3.162

5.  Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

Authors:  Jay B Fell; John P Fischer; Brian R Baer; James F Blake; Karyn Bouhana; David M Briere; Karin D Brown; Laurence E Burgess; Aaron C Burns; Michael R Burkard; Harrah Chiang; Mark J Chicarelli; Adam W Cook; John J Gaudino; Jill Hallin; Lauren Hanson; Dylan P Hartley; Erik J Hicken; Gary P Hingorani; Ronald J Hinklin; Macedonio J Mejia; Peter Olson; Jennifer N Otten; Susan P Rhodes; Martha E Rodriguez; Pavel Savechenkov; Darin J Smith; Niranjan Sudhakar; Francis X Sullivan; Tony P Tang; Guy P Vigers; Lance Wollenberg; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2020-04-06       Impact factor: 7.446

6.  The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

Authors:  Nicole F Neel; Timothy D Martin; Jeran K Stratford; Tanya P Zand; David J Reiner; Channing J Der
Journal:  Genes Cancer       Date:  2011-03

7.  Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.

Authors:  Loren D Walensky; Andrew L Kung; Iris Escher; Thomas J Malia; Scott Barbuto; Renee D Wright; Gerhard Wagner; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Science       Date:  2004-09-03       Impact factor: 47.728

Review 8.  Distinct requirements for Ras oncogenesis in human versus mouse cells.

Authors:  Nesrin M Hamad; Joel H Elconin; Antoine E Karnoub; Wenli Bai; Jeremy N Rich; Robert T Abraham; Channing J Der; Christopher M Counter
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

9.  Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design.

Authors:  S Marqusee; R L Baldwin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

10.  The CCPN data model for NMR spectroscopy: development of a software pipeline.

Authors:  Wim F Vranken; Wayne Boucher; Tim J Stevens; Rasmus H Fogh; Anne Pajon; Miguel Llinas; Eldon L Ulrich; John L Markley; John Ionides; Ernest D Laue
Journal:  Proteins       Date:  2005-06-01
View more
  1 in total

Review 1.  RLIP76: A Structural and Functional Triumvirate.

Authors:  Jasmine Cornish; Darerca Owen; Helen R Mott
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.